Relevant bibliographies by topics / Response to therapies

Academic literature on the topic 'Response to therapies'

Author: Grafiati
Published: 7 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Response to therapies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Journal articles on the topic "Response to therapies":

1

Gayan, Chathura. "Evaluate the response of Apoptosis, Angiogenesis and Cancer Therapies." Cancer Research and Cellular Therapeutics 2, no. 1 (March 28, 2018): 01–08. http://dx.doi.org/10.31579/2640-1053/022.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Angiogenesis, the growth of new blood vessels from the existing vasculature, and is maintained in adult tissues by the balanced presence of both angiogenic inducers and inhibitors in the tissue milieu. When inducers predominate, vascular endothelial cells (VECs) become activated and in this activated VECs, distinct cell signaling pathways are initiated providing the specificity of anti-angiogenic therapies to the tumor vasculature. VEC apoptosis has been well documented in regressing vessels, and it has been shown that, in addition to activating the VECs, some inducers such as vascular endothelial growth factor also up-regulate Fas expression, thus sensitizing the cell to apoptotic stimuli. Endogenous angiogenesis inhibitors, such as thrombospondin-1(TSP-1) and pigment epithelium-derived factor (PEDF), stimulate signaling cascades within the VECs and also induce the expression of Fas ligand in activated VECs. Therefore, when inhibitors predominate, the apoptotic cascade is initiated ,thus anti-angiogenic therapies can target the inducer supply or directly target the VECs. Although clinical studies suggest that anti-angiogenic therapies may prove to be most effective when used in combination with traditional therapies
2

Dudekula, Noor, Vikas Arora, Zsuzsanna Callaerts-Vegh, and Richard A. Bond. "The Temporal Hormesis of Drug Therapies." Dose-Response 3, no. 3 (May 1, 2005): dose—response.0. http://dx.doi.org/10.2203/dose-response.003.03.009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Recent publications in the field of asthma therapeutics and studies performed over the last decade in the treatment of chronic heart failure suggest a phenomenon called ‘temporal hormesis’. This phenomenon can be defined as the beneficial action of drug after chronic administration as opposed to its detrimental acute effects. Temporal hormesis may be related to the classification of the drug molecule as an agonist, antagonist or an inverse agonist. This phenomenon may be a more general principal applicable in the treatment of other diseases apart from asthma and chronic heart failure.
3

Truelove, Edmond, Kimberly Hanson Huggins, Lloyd Mancl, and Samuel F. Dworkin. "NONSPLINT THERAPIES: Authors' response." Journal of the American Dental Association 137, no. 11 (November 2006): 1493–94. http://dx.doi.org/10.14219/jada.archive.2006.0070.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Prasad, Vinay, Victoria Kaestner, and Alyson Haslam. "Bridging therapies used in trials testing CAR-T therapies." Journal of Clinical Oncology 42, no. 16_suppl (June 1, 2024): e19011-e19011. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e19011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
e19011 Background: Chimeric Antigen Receptor T-cell (CAR-T) therapy can induce durable remission in some patients but requires time for a patient’s own cells to be reengineered to produce CAR proteins that can bind to and destroy cancer cells. During this time, bridging therapy is often used in debulking to reduce treatment toxicities and to control the disease while waiting for the manufacturing of CAR-T cells. Because bridging therapy often involves systemic treatment, the bridging therapies can induce responses, in and of themselves, in clinical trials testing CAR-T therapies. As such, we sought to assess bridging therapies used in CAR-T trials. Methods: Using the FDA labels (labels.fda.gov) to identify the indications and the pivotal clinical trials that led to the approval of each CAR-T cell therapy, we looked at which bridging therapies were used, whether multiple therapies were combined, response rates, and the reported adverse events associated with bridging therapy. We took note of all relevant comments regarding bridging therapy in the main paper and supplemental results. Results: Of the 11 studies testing CAR-T therapies, 10 reported the bridging therapies that were used in the study. Notably, only three of 11 studies provided clear information about which combinations of bridging therapy treatments were used during the trials. Of those that reported the types of bridging therapies (n=10), the most commonly used bridging therapy was dexamethasone, which was used in every study (10/10). The next three most commonly used treatments include rituximab (6/10), gemcitabine (5/10), and etoposide (5/10). Of the trials, 2/11 clearly reported whether patients had a complete response (CR), partial response (PR), or very good partial response (VGPR) to bridging therapy. 5/11 vaguely reported responses, using terminology outside of CR, PR, VGPR. 4/11 trials did not report or mention any response information in regards to bridging therapy. Of all the trials, 1/11 clearly reported adverse events associated with bridging therapy in the supplement, while 10/11 of the trials listed adverse events associated with the treatment groups, without clarifying those associated with bridging. Conclusions: Although patients are often refractory to first-line therapies, which share considerable overlap with the bridging therapies used, these therapies may still induce responses. Despite this possibility, the reporting of bridging therapy combinations and their subsequent response rates and adverse event rates, is highly variable. Of 11 pivotal clinical trials that led to the approval of a CAR-T cell therapy, none clearly reported bridging therapy data that encompassed all three categories (combinations used, response rates, adverse events). What is more, these data were often omitted completely. These findings highlight the need for greater transparency in the reporting of bridging therapy in order to more reliably assess the efficacy of CAR-T therapies.
5

Brown, Barbara G. "Innovative Therapies: Biological Response Modifiers." Journal of the Association of Pediatric Oncology Nurses 5, no. 1-2 (January 1988): 26. http://dx.doi.org/10.1177/104345428800500109.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Mattison, Lars, and Paul Iaizzo. "PHRENIC NERVE RESPONSE TO CRYOABLATION THERAPIES." Journal of the American College of Cardiology 65, no. 10 (March 2015): A405. http://dx.doi.org/10.1016/s0735-1097(15)60405-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Cunningham, Jonathan W., and Peder L. Myhre. "NT-proBNP Response to Heart Failure Therapies." Journal of the American College of Cardiology 78, no. 13 (September 2021): 1333–36. http://dx.doi.org/10.1016/j.jacc.2021.07.045.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Gerger, Armin, Melissa LaBonte, and Heinz-Josef Lenz. "Molecular Predictors of Response to Antiangiogenesis Therapies." Cancer Journal 17, no. 2 (March 2011): 134–41. http://dx.doi.org/10.1097/ppo.0b013e318212db3c.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Held, Barbara S. "Common dances, uncommon therapies: Response to Ryder." Journal of Family Psychology 1, no. 4 (1988): 476–79. http://dx.doi.org/10.1037/h0084983.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Johnston, Stephen R. D., Alexandra Leary, Lesley-Ann Martin, Ian E. Smith, and Mitch Dowsett. "Enhancing endocrine response with novel targeted therapies." Cancer 112, S3 (2008): 710–17. http://dx.doi.org/10.1002/cncr.23190.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources
You might also be interested in the extended bibliographies on the topic 'Response to therapies' for particular source types:
Journal articles Dissertations / Theses Books

Dissertations / Theses on the topic "Response to therapies":

1

Massó, Vallés Daniel. "Inhibiting Myc and the Myc dependent inflammatory response as cancer therapies." Doctoral thesis, Universitat Autònoma de Barcelona, 2017. http://hdl.handle.net/10803/458137.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Aquesta tesi s’ha realitzat al Laboratori de Modelització de Teràpies Anti-tumorals en Ratolí dirigit per la Dra. Laura Soucek al Programa de Recerca Preclínica del Vall d’Hebron Institut d’Oncologia (VHIO), i comprèn dos projectes diferenciats centrats en dues de les funcions oncogèniques de Myc. Pel que fa al primer projecte, hem validat farmacològicament la inhibició dels mastòcits com a estratègia terapèutica contra l’adenocarcinoma ductal de pàncrees (PDAC). Per a fer-ho, hem utilitzat ibrutinib, un inhibidor de la tirosina quinasa de Bruton (BTK) en models de ratolí de PDAC, el tumor de pàncrees més comú i agressiu. El tractament amb ibrutinib inhibeix la desgranulació dels mastòcits, redueix la proliferació i la infiltració leucocitària a l’estroma del tumor i redueix dràsticament la deposició de col·lagen. En models de PDAC fibrosos, tant transgènics com derivats de pacients, ibrutinib allarga la supervivència i és sinèrgic amb la quimioteràpia, demostrant l’aplicabilitat clínica d’aquest fàrmac enfront del càncer de pàncrees. Aquest projecte a portat a la publicació d’un article científic i un editorial (Masso-Valles et al. 2015; Masso-Valles et al. 2016), a més de contribuir a la posada en marxa d’assajos clínics per testar la combinació d’ibrutinib i quimioteràpia en pacients amb PDAC metastàtic (fase 1/2: NCT02562898 i fase 2/3: NCT02436668). El segon projecte està centrat en la relació entre Myc i la metàstasi. Hem estudiat el potencial d’Omomyc, un mutant dominant negatiu de Myc que ha demostrat una eficàcia extraordinària enfront a tumors primaris en diversos models de ratolí, contra el càncer de mama metastàtic. Hem demostrat que la inhibició de Myc mitjançant Omomyc és una teràpia segura i eficaç contra el càncer de mama, impedint la proliferació cel·lular, l’angiogènesi, la migració i la invasió in vitro, reduint dramàticament el creixement dels tumors primaris i les metàstasis en ratolins immunodeprimits, fins i tot erradicant metàstasis establertes, i impedint gairebé completament la formació de tumors primaris i metàstasis en ratolins immunocompetents. D’aquesta manera, hem demostrat per primera vegada l’aplicabilitat d’Omomyc enfront de les metàstasis, en contra de la noció preestablerta que la inhibició de Myc podria potenciar, enlloc d’inhibir, el procés d’invasió. Finalment, hem validat TMTP1-Omomyc com el primer fàrmac basat en Omomyc administrable directament per al tractament del càncer de mama metastàtic triple negatiu, proporcionant una nova oportunitat terapèutica per als pacients que pateixen aquesta malaltia devastadora i incurable.
The work of this thesis was carried out in the Mouse Models of Cancer Therapies Laboratory led by Dr. Laura Soucek in the Preclinical Research Program of the Vall d’Hebron Institute of Oncology (VHIO), and comprises two differentiated parts centered on two oncogenic functions of Myc. In the first project we validated the pharmacological inhibition of mast cells as a therapeutic strategy against pancreatic ductal adenocarcinoma (PDAC). To do so, we made use of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib in mouse models of PDAC, the most common and aggressive pancreatic tumor. Treatment with ibrutinib inhibited mast cell degranulation, reduced cell proliferation and leukocytic infiltration in the tumor stroma and dramatically reduced collagen deposition. In fibrotic mouse models of PDAC, both genetically-engineered and patient-derived, ibrutinib extended survival and synergized with chemotherapy, demonstrating the clinical applicability of this drug against pancreatic cancer. This project has led to the publication of a research paper and an editorial (Masso-Valles et al. 2015; Masso-Valles et al. 2016), as well as contributing to the initiation of clinical trials combining ibrutinib with chemotherapy in patients with metastatic PDAC (phase 1/2: NCT02562898 and phase 2/3: NCT02436668). The second project is focused on the relationship between Myc and metastasis. We studied de potential of Omomyc, a Myc dominant negative mutant that had shown extraordinary efficacy against primary tumors in multiple mouse models, against metastatic breast cancer. We demonstrated that Myc inhibition by Omomyc is a safe and effective therapy against breast cancer by impairing cell proliferation, angiogenesis, migration and invasion in vitro, dramatically reducing primary tumor and metastatic growth in immunocompromised mice, even eradicating established metastases, and preventing primary tumor and metastatic formation almost completely in immunocompetent mice. Thus, we have demonstrated for the first time the applicability of Omomyc against metastasis, challenging the pre-established notion that Myc inhibition could potentiate, rather than inhibit, invasion. Finally, we have validated TMTP1-Omomyc as the first direct-deliverable Omomyc-based drug for the treatment of metastatic triple negative breast cancer, providing a new therapeutic opportunity for patients suffering from this dreadful and incurable disease.
2

FATIMA, RIZWAN NARJIS. "Targeting the integrated stress response (ISR) as a therapeutic option for chronic lymphocytic leukemia." Thesis, The University of Sydney, 2021. https://hdl.handle.net/2123/25009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
The mechanisms behind development of drug resistance in B-Chronic lymphocytic leukemia (CLL) are unclear and need research to find better treatment options. BCR signalling lead to activation of MEK/ERK, PI3K/AKT pathways and reduced apoptosis through BCL2 pathway. Studies have shown that integrated stress response (ISR) also stimulates oncogenic signalling. This thesis was aimed at understanding the mechanisms of action of some novel drugs that can inhibit CLL proliferation by targeting the BCR and ISR pathways in presence of an in vitro CLL tumor microenvironment (TME). We have shown induction of CLL-specific apoptosis by a novel imipridone, ONC-212, by targeting specific proteins of ISR, together with inhibition of BCL2 and MAPK/ERK pathways. In the following chapter, the effects of another imipridone, TR57, were investigated in combination with BCL2 inhibitor, venetoclax. We exhibited synergistic effect of this combination on normal and high risk primary CLL. Studies on TP53 deficient CLL cell line and patient cells with 17p deletion / TP53 mutations showed similar results indicating the efficacy of this combination is independent of TP53 status. We showed upregulation of ATF4, TRAIL, and down-regulation of HSP90, HSP60, Grp78 proteins in cells treated with TR57 alone and in combination with venetoclax. Our study suggests targeting both BCL2 and ISR has therapeutic potential for the treatment of high risk or relapsed/refractory CLL. The next chapter focuses on a stress regulatory enzyme HYPE. HYPE modifies proteins with AMP in a post translational modification, ‘AMPylation’. We ablated the HYPE gene in the OSU-CLL cell line using CRISPR-Cas9 to study the role of AMPylation in mediating the effects of fludarabine. HYPE KO cells showed more sensitivity to fludarabine compared to WT CLL cells. We also performed a global proteome analysis (using TMT labelled mass spectrometry) of CLL cell lines in presence and absence of the TP53 gene after treating them with a chemotherapeutic drug, fludarabine. Less downregulation of apoptotic inducing DNA licencing factors in TP53 KO cells compared with WT cells understand fludarabine resistance in CLL. In conclusion, this thesis highlights how the integrated stress response could be targeted for the treatment of relapsed/refractory, drug resistant and high risk CLL disease
3

Nji, Akindeh Mbuh. "Modeling response and delayance to parasite clearance time to artemisinin combination therapies(ACT)." Diss., Ludwig-Maximilians-Universität München, 2013. http://nbn-resolving.de/urn:nbn:de:bvb:19-168213.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Randall, Adrian Joseph. "A systems approach to uncovering the adaptive response of cancer to targeted therapies." Thesis, Massachusetts Institute of Technology, 2012. http://hdl.handle.net/1721.1/72967.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Thesis (S.M.)--Massachusetts Institute of Technology, Computational and Systems Biology Program, 2012.
Cataloged from PDF version of thesis.
Includes bibliographical references (p. 47-53).
Tyrosine kinase inhibitors have significant promise in the fight to develop agents that can target cancer in a tumor-specific manner. A number of drugs have been and are currently in development to inhibit specific kinases that can mediate uncontrolled proliferation; however, an unfortunate eventuality for most patients receiving these treatments is the development of resistance that renders these drugs almost completely ineffective. While a number of mechanisms can evolve within a tumor to mitigate effects of kinase inhibitors, we sought to uncover what changes are occurring in the tyrosine phosphorylation network at both short timescales (minutes to 72 hours) and long timescales (120 hours+) that can be playing a role in helping a tumor become resistant to driver-kinase inhibition. It is our hypothesis that specific feedback networks are able to detect and overcome driver kinase inhibition through activation of potential other pathways, which can go on to mediate a longer term resistance phenotype. In order to probe dynamics in the tyrosine phosphorylation network, we employed mass spectrometry to analyze peptides derived from six non-small cell lung cancer cell lines that we classify as either EGFR+ or EML4-ALK+. From both mass spectrometry data and growth assays, we identified an unintuitive boost in signaling and growth in response to low inhibitor concentrations, suggestive of a cellular mechanism that is adaptive to driver kinase inhibition. Studies of EML4-ALK driven H3122 cells showed that this short-term response is not the same as the known long-term resistance mechanism to ALK inhibition, leading support to the notion that the short-term "adaptive response" may be a novel type of mechanism to aid tumor adaptation to targeted therapies. In an effort to better probe signaling events occurring downstream of the phosphotyrosine network, a new pull down technique for mass spectrometry using 14-3-3 protein against phosphoserine and phosphothreonine peptides is described. The results of these studies open up many potential avenues for further exploration into the immediate and long-term signaling response of cancer to targeted therapies.
by Adrian Joseph Randall.
S.M.
5

Breen, Michael Scott. "TISSUE RESPONSE TO INTERVENTIONAL MRI-GUIDED THERMAL ABLATION THERAPY." Case Western Reserve University School of Graduate Studies / OhioLINK, 2004. http://rave.ohiolink.edu/etdc/view?acc_num=case1080938405.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Reddy, Papari Prashanth. "Non-motor symptoms in advanced Parkinson's : the natural history and response to advanced therapies." Thesis, King's College London (University of London), 2015. http://kclpure.kcl.ac.uk/portal/en/theses/nonmotor-symptoms-in-advanced-parkinsons(b82ce682-b4f0-424d-9c7e-9f293b11bc18).html.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Background and Method Non-motor symptoms (NMS) are a key determinant of health related quality of life (HrQoL) in Parkinson’s disease (PD) (Martinez-Martin et al., 2011) and are present in virtually every PD patient. Many aspects of NMS are treatable by dopaminergic drugs (Chaudhuri and Schapira, 2009) and treating NMS remains a key unmet need. (Chaudhuri et al., 2011) Currently treatment choices in advanced PD are Apomorphine (Apo), intra-jejunal levodopa infusion (IJLI) and Deep brain stimulation of the subthalamic nucleus (DBS-STN) and are solely recommended based on motor symptoms. This thesis addresses a range of comparative multicentre, international collaborative studies of real life dopaminergic therapies in PD with a focus on non-motor effects. Non-motor effect has been measured using the validated PD non-motor symptoms scale (NMSS). (Chaudhuri et al., 2007) The largest real life worldwide study with a long-term longitudinal follow-up design addresses a key unmet need with over 40 patients in each arm. Using regression analysis and comparative measures, effects on motor function, quality of life were compared and contrasted with non-motor effects. A patient reported outcome tool was developed using the same cohort of patients. Results and Conclusion This project has shown the beneficial effects of Apo, IJLI and DBS-STN therapies on aspects of NMS in advanced Parkinson’s that translate to a robust improvement in the HrQoL. For the first time we show that there are differences between Apo, a dopamine agonist based therapy versus IJLI (a levodopa therapy) on aspects of NMS and this would need to be explored further. The effects could be explained by a central dopaminergic effect and effective treatment of NMS arising from non-motor fluctuations. (Storch et al., 2013) Choice of advanced therapies in PD should therefore take into account their non-motor effects and patient expectations along with improvement of motor symptoms.
7

Fenton, Audrey C. "The role of oncogenic kras as a determinant of response to EGER?HER2 targeted therapies." Thesis, Queen's University Belfast, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.534743.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Cramer, Megan L. "Novel signaling pathways in skeletal muscle: Modifiers of disease and the immune response to therapies." The Ohio State University, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=osu1531790292235549.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

McNally, Jonathan P. "The rational targeting of the DNA damage response pathway for the selective elimination of encephalitogenic T cells." University of Cincinnati / OhioLINK, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1428652709.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Beshir, Kahlid Bushra. "Genetic polymorphisms in 'Plasmodium falciparum' associated with reduced response to artemisinin combination therapies in Western Kenya." Thesis, London School of Hygiene and Tropical Medicine (University of London), 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.558359.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Response to therapies":

1

Janusz, Rak, ed. Oncogene-directed therapies. Totowa, N.J: Humana Press, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Loes, Michael, and Michael W. Loes. The healing response. Topanga, Calif: Freedom Press, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Castro, Antonio de Miguel. Clopidogrel response in acute coronary syndrome: Clinical implications and emerging therapies. Hauppauge, N.Y: Nova Science Publishers, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

A, Foon Kenneth, and Muss Hyman B, eds. Biological and hormonal therapies of cancer. Boston: Kluwer Academic Publishers, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

L, Goldstein Allan, Garaci E, Institute for Advanced Studies in Immunology & Aging., and International Symposium on Combination Therapies (1st : 1991 : Washington, D.C.), eds. Combination therapies: Biological response modifiers in the treatment of cancer and infectious diseases. New York: Plenum Press, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

L, Goldstein Allan, Garaci E, Institute for Advanced Studies in Immunology & Aging., and International Symposium on Combination Therapies (2nd : 1992 : Acireale, Italy), eds. Combination therapies 2: Biological response modifiers in the treatment of cancer and infectious diseases. New York: Plenum Press, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Howard, Brody. The placebo response: How you can release the body's inner pharmacy for better health. New York: Cliff Street Books, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Valentine, Tom. Applied kinesiology: Muscle response in diagnosis, therapy and preventive medicine. Rochester, Vt: Thorsons Publishers, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Valentine, Tom. Applied kinesiology: Muscle response in diagnosis, therapy, and preventive medicine. Rochester, Vt: Healing Arts Press, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kradin, Richard L. The placebo response and the power of unconscious healing. New York: Routledge, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Response to therapies":

1

Hsia, Judith, and Ting Tang. "Aspirin as a Biological Response Modifier." In Combination Therapies, 131–37. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3340-5_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Cassone, Antonio, Antonella Torosantucci, Carla Palma, Maria J. Gomez, Clara M. Ausiello, and Julie Y. Djeu. "Cell Wall Constituents of Candida Albicans as Biological Response Modifiers." In Combination Therapies, 159–66. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3340-5_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Venditti, Adriano, Maria Teresa Scimo, Giovanni Del Poeta, Roberto Stasi, Ugo Coppetelli, Mario Masi, Manrico Cecconi, et al. "Biological Response Modifiers and Differentiating Agents in Myelodisplastic Syndromes." In Combination Therapies 2, 171–77. Boston, MA: Springer US, 1993. http://dx.doi.org/10.1007/978-1-4615-2964-4_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kirkley, J. E., Paul H. Naylor, Dante J. Marciani, Charlotte R. Kensil, Mark Newman, and A. L. Goldstein. "QS-21 Augments the Antibody Response to a Synthetic Peptide Vaccine Compared to Alum." In Combination Therapies, 231–36. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3340-5_28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Nakanishi, Toshio. "Thromboembolism in Cyanotic Heart Disease: Mechanisms and Therapies." In Inflammatory Response in Cardiovascular Surgery, 349–53. London: Springer London, 2013. http://dx.doi.org/10.1007/978-1-4471-4429-8_41.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Zhang-Hoover, Jie, and Joan Stein-Streilein. "Therapies Based on Principles of Ocular Immune Privilege." In Immune Response and the Eye, 317–27. Basel: KARGER, 2007. http://dx.doi.org/10.1159/000099281.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mutchnick, Milton G., J. I. Jaurequi, and David A. Shafritz. "Sustained Response to Thymosin Therapy in Patients with Chronic Active Hepatitis B." In Combination Therapies 2, 217–23. Boston, MA: Springer US, 1993. http://dx.doi.org/10.1007/978-1-4615-2964-4_26.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Stolfi, Vito M., Jeffrey W. Milsom, James H. Finke, Victor W. Fazio, Luca Ferraris, and Claudio Fiocchi. "The Biological Response Modifiers Interleukin-2 and Tumor Necrosis Factor-α Modulate the Cytotoxic Activity of Tumor Infiltrating Lymphocytes Against Human Colon Cancer Cells." In Combination Therapies, 245–51. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3340-5_30.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ravagnan, Giampietro, Roberto Falchetti, Paolo Di Francesco, Roberta Gaziano, Giulia Lanzilli, Cartesio Favalli, and Enrico Garaci. "Effect of Thymosin α 1 on Cocaine-Induced Inhibition of T-Cell Dependent Murine Immune Response." In Combination Therapies 2, 61–66. Boston, MA: Springer US, 1993. http://dx.doi.org/10.1007/978-1-4615-2964-4_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wood, Laura L. "Empirical Research Considerations in Drama Therapy: A Response Essay." In Arts Therapies in Psychiatric Rehabilitation, 155–57. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-76208-7_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Response to therapies":

1

Berceli, Scott A., and Alexander W. Clowes. "Intimal Hyperplasia — Development and Regression in Response to Fluid Shear." In ASME 1999 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 1999. http://dx.doi.org/10.1115/imece1999-0381.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Abstract The long-term success of autogenous and prosthetic bypass grafts is dictated by the development and subsequent progression of intimal hyperplasia. While recent advances in vascular biology continue to improve our understanding of the mechanisms which control this process, available clinical therapies which treat or slow its progression have yet to be identified. Among the factors which influence the development of intimal hyperplasia are the physical forces exposed to bypass conduits. As initially described by Glagov et al. (1988) and confirmed by multiple other investigators, the biology of the hyperplastic response is modulated by the imposed fluid shearing forces While our ability to modulate the local hemodynamics of bypass conduits is limited, an understanding of how these forces govern the healing response can serve as a basis for future pharmacological therapies. In our laboratory we have employed a primate model to understand the influence of shear stress on the development of intimal hyperplasia in PTFE grafts.
2

RUSSO, MARIANGELA, Giovanni Crisafulli, Alberto Sogari, Nicole Megan Reilly, Sabrina Arena, Simona Lamba, Alice Bartolini, et al. "Abstract A120: Adaptive mutability of colorectal cancers in response to targeted therapies." In Abstracts: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 26-30, 2019; Boston, MA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1535-7163.targ-19-a120.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Johnsen, Hannah, Aphrothiti Hanrahan, Alexis Jones, and David Solit. "Abstract 36: Functional characterization of ERBB2 mutations and response to targeted therapies." In Abstracts: AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy; June 13-16, 2015; Salt Lake City, UT. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1557-3265.pmsclingen15-36.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

LAURET, Simon, Laurent Guilleminault, Elise Noel-Savina, Gregoire Prevot, Danielle Brouquieres, and Alain Didier. "Are serum immunoglobulins a predictive biomarker of response for anti-IL5 therapies?" In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.2266.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Dunne, Victoria L., Niamh McGivern, Kienan I. Savage, Nuala McCabe, and Richard Kennedy. "Abstract 3163: The role of early response genes (ERG’s) as a biomarker of response to Wee1 targeted therapies." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-3163.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dunne, Victoria L., Niamh McGivern, Kienan I. Savage, Nuala McCabe, and Richard Kennedy. "Abstract 3163: The role of early response genes (ERG’s) as a biomarker of response to Wee1 targeted therapies." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-3163.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bardelli, Alberto. "Abstract PL06-01: Liquid biopsies to monitor response and resistance to targeted therapies." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-pl06-01.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Price, D., E. Sims, L. Kemp, J. von Ziegenweidt, T. Fan, and AJ Lee. "Impact of Smoking and Rhinitis on Response to Therapies in Patients with Asthma." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a5695.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ito, Shuku-ei A., Hidekazu Shirota, and Chikashi Ishioka. "Abstract 1454: IL-4 modulate the tumor microenvironment and response to cancer therapies." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-1454.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Rosa, Rogerio S., Rafael H. S. Santos, Adamo Y. Brito, and Katia S. Guimaraes. "Insights on prediction of patients' response to anti-HIV therapies through machine learning." In 2014 International Joint Conference on Neural Networks (IJCNN). IEEE, 2014. http://dx.doi.org/10.1109/ijcnn.2014.6889659.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Response to therapies":

1

McCawley, Lisa. Breast Cancer Tissue Bioreactor for Direct Interrogation and Observation of Response to Antitumor Therapies. Fort Belvoir, VA: Defense Technical Information Center, July 2011. http://dx.doi.org/10.21236/ada552540.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zhu, Zhihong, Yue Zhuo, Haitao Jin, Boyu Wu, and Zhijie Li. Chinese Medicine Therapies for Neurogenic Bladder after Spinal Cord Injury: A protocol for systematic review and network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2021. http://dx.doi.org/10.37766/inplasy2021.8.0084.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Neurogenic bladder (NB), a refractory disease, is characterized by voiding dysfunction of bladder and/or urethra, and spinal cord injury (SCI) is a common cause. Chinese medicine therapies have been applied extensively in the treatment of neurogenic bladder, especially in China, and the results are promising but varying. Thus, the aim of this work is to assess the efficacy and safety of various Chinese medicine therapies for neurogenic bladder after spinal cord injury. Condition being studied: Chinese medicine therapies; Neurogenic bladder after spinal cord injury. Main outcome(s): The primary outcome of our NMA will be measured by overall response rate and urodynamic tests, which includes postvoiding residual urine volume, maximum urinary flow rate, and maximal detrusor pressure.
3

WANG, Xuesong, Xuliang SHI, Jing LV, Juncha ZHANG, Yongli HUO, Guang ZUO, Guangtong LU, Cunzhi LIU, and Yanfen SHE. Acupuncture and Related Therapies for anxiety and depression in Diarrhoea-Predominant Irritable Bowel Syndrome(IBS-D): A Network Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2022. http://dx.doi.org/10.37766/inplasy2022.3.0162.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Review question / Objective: Acupuncture-related therapies are effective Diarrhoea-Predominant Irritable Bowel Syndrome(IBS-D), therefore, our aim was to evaluate and rank the effect of different acupuncture-related therapies for the anxiety-depression status of IBS-D patients. Eligibility criteria: The published randomized controlled trials (RCTs) of acupuncture-related therapies for the treatment of IBS-D, regardless of age and sex. Clear diagnostic criteria were required to confirm the diagnosis of IBS-D, Such as Rome I, Rome II, Rome III, Rome IV, and Chinese expert consensus. Interventions in the treatment group included various types of acupuncture-related therapies, including simple acupuncture (ACU), electroacupuncture (EA), warm acupuncture (WA), moxibustion (MOX), or a combination of acupuncture and drugs; the control group is anti-diarrheal or anti-spasmodic western medicine, or placebo, or comparison between various acupuncture-related therapies. The results of the report are required to include at least one of the following outcome indicators: (1) primary outcome: Hamilton anxiety rating scale( HAMA), hamilton depression rating scale(HAMD), self-rating anxiety scale (SAS), self-rating depression scale(SDS), secondary outcome: Response rate. The language of the publication was limited to Chinese or English.
4

FDG-PET/CT SUV for Response to Cancer Therapy, Clinically Feasible Profile. Chair Nathan Hall and Jeffrey Yap. Radiological Society of North America (RSNA) / Quantitative Imaging Biomarkers Alliance (QIBA), June 2023. http://dx.doi.org/10.1148/qiba/20230615.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
This QIBA Profile documents specifications and requirements to provide comparability and consistency for quantitative FDG-PET across scanners in oncology. It can be applied to both clinical trial use as well as individual patient management. This document organizes acquisition, reconstruction and post-processing, analysis and interpretation as steps in a pipeline that transforms data to information to knowledge. The document, developed through the efforts of the QIBA FDG-PET Biomarker Committee, has shared content with the FDG-PET UPICT protocol, as well as additional material focused on the devices used to acquire and analyze the FDG-PET data. The QIBA acquisition protocol is largely derived from the FDG-PET UPICT protocol for FDG-PET imaging in clinical trials. In the UPICT protocol, there is a carefully developed hierarchy with tiered levels of protocol compliance. This reflects the recognition that there are valid reasons to perform trials using different levels of rigor, even for the same disease/intervention combination. For example, a high level of image measurement precision may be needed in small, early-phase trials whereas a less rigorous level of precision may be acceptable in large, late-phase trials of the same drug in the same disease setting. This Profile defines the behavioral performance levels and quality control specifications for whole-body FDG-PET/CT scans used in single- and multi-center clinical trials of oncologic therapies. While the emphasis is on clinical trials, this process is also intended to apply for clinical practice. The specific claims for accuracy are detailed in the Claims section. A motivation for the development of this Profile is that while a typical PET/CT scanner measurement system (including all supporting devices) may be stable over days or weeks, this stability cannot be expected over the time that it takes to complete a clinical trial. In addition, there are well known differences between scanners and or the operation of the same type of scanner at different imaging sites. The intended audiences of this document include: Technical staff of software and device manufacturers who create products for this purpose Biopharmaceutical companies, oncologists, and clinical trial scientists designing trials with imaging endpoints Clinical research professionals Radiologists, nuclear medicine physicists, technologists, physicists and administrators at healthcare institutions (1) considering specifications for procuring new PET/CT equipment, (2) designing PET/CT acquisition protocols, (3) making quantitative measurements from PET/CT images Regulators, nuclear medicine physicians, oncologists, and others making decisions based on quantitative image measurements
5

Shujaa, Asaad Suliman, and Qasem Almulihi. The efficacy and safety of ketamine in treating refractory and super-refractory status epilepticus in pediatric and adult populations, A systemic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2022. http://dx.doi.org/10.37766/inplasy2022.11.0011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Review question / Objective: This study is to assess the efficacy and safety of ketamine in treating refractory and super-refractory status epilepticus in pediatric and adult populations. Rationale: Refractory status epilepticus (RSE) is either generalized or complex partial status epilepticus (SE) that fails to respond to first and second-line therapies. Super refractory status epilepticus (SRSE) is SE that remains unresponsive despite 24 hours of therapy with general anesthesia [1, 2]. Both RSE and SRSE pose significant challenges for the managing intensivist. There exists a race against time for control of epileptic activity in the RSE/SRSE patient to preserve cortical function and reduce morbidity/mortality. However, despite the best intentions, and not uncommonly, standard frontline antiepileptic drugs (AEDs) fail to control or reduce seizure activity once seizures approach the 30-minute mark. The following review provides an analysis of ketamine in treating RSE/SRSE, focusing on the potential target population, dosing, concerns, and the role of early administration.
6

Chou, Roger, Rongwei Fu, Tracy Dana, Miranda Pappas, Erica Hart, and Kimberly M. Mauer. Interventional Treatments for Acute and Chronic Pain: Systematic Review. Agency for Healthcare Research and Quality (AHRQ), September 2021. http://dx.doi.org/10.23970/ahrqepccer247.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Objective. To evaluate the benefits and harms of selected interventional procedures for acute and chronic pain that are not currently covered by the Centers for Medicare & Medicaid Services (CMS) but are relevant for and have potential utility for use in the Medicare population, or that are covered by CMS but for which there is important uncertainty or controversy regarding use. Data sources. Electronic databases (Ovid® MEDLINE®, PsycINFO®, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews) to April 12, 2021, reference lists, and submissions in response to a Federal Register notice. Review methods. Using predefined criteria and dual review, we selected randomized controlled trials (RCTs) for 10 interventional procedures and conditions that evaluated pain, function, health status, quality of life, medication use, and harms. Random effects meta-analysis was conducted for vertebral compression fracture; otherwise, outcomes were synthesized qualitatively. Effects were classified as small, moderate, or large using previously defined criteria. Results. Thirty-seven randomized trials (in 48 publications) were included. Vertebroplasty (13 trials) is probably more effective at reducing pain and improving function in older (>65 years of age) patients, but benefits are small (less than 1 point on a 10-point pain scale). Benefits appear smaller (but still present) in sham-controlled (5 trials) compared with usual care controlled trials (8 trials) and larger in trials of patients with more acute symptoms; however, testing for subgroup effects was limited by imprecision. Vertebroplasty is probably not associated with increased risk of incident vertebral fracture (10 trials). Kyphoplasty (2 trials) is probably more effective than usual care for pain and function in older patients with vertebral compression fracture at up to 1 month (moderate to large benefits) and may be more effective at >1 month to ≥1 year (small to moderate benefits) but has not been compared against sham therapy. Evidence on kyphoplasty and risk of incident fracture was conflicting. In younger (below age for Medicare eligibility) populations, cooled radiofrequency denervation for sacroiliac pain (2 trials) is probably more effective for pain and function versus sham at 1 and 3 months (moderate to large benefits). Cooled radiofrequency for presumed facet joint pain may be similarly effective versus conventional radiofrequency, and piriformis injection with corticosteroid for piriformis syndrome may be more effective than sham injection for pain. For the other interventional procedures and conditions addressed, evidence was too limited to determine benefits and harms. Conclusions. Vertebroplasty is probably effective at reducing pain and improving function in older patients with vertebral compression fractures; benefits are small but similar to other therapies recommended for pain. Evidence was too limited to separate effects of control type and symptom acuity on effectiveness of vertebroplasty. Kyphoplasty has not been compared against sham but is probably more effective than usual care for vertebral compression fractures in older patients. In younger populations, cooled radiofrequency denervation is probably more effective than sham for sacroiliac pain. Research is needed to determine the benefits and harms of the other interventional procedures and conditions addressed in this review.
7

Sionov, Edward, Nancy Keller, and Shiri Barad-Kotler. Mechanisms governing the global regulation of mycotoxin production and pathogenicity by Penicillium expansum in postharvest fruits. United States Department of Agriculture, January 2017. http://dx.doi.org/10.32747/2017.7604292.bard.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
The original objectives of the study, as defined in the approved proposal, are: To characterize the relationship of CreA and LaeA in regulation of P T production To understand how PacC modulates P. expansumpathogenicity on apples To examine if other secondary metabolites are involved in virulence or P. expansumfitness To identify the signaling pathways leading to PAT synthesis Penicilliumexpansum, the causal agent of blue mould rot, is a critical health concern because of the production of the mycotoxinpatulin (PAT) in colonized apple fruit tissue. Although PAT is produced by many Penicilliumspecies, the factors activating its biosynthesis were not clear. This research focused on host and fungal mechanisms of activation of LaeA (the global regulator of secondary metabolism), PacC (the global pH modulator) and CreA (the global carbon catabolite regulator) on PAT synthesis with intention to establish P. expansumas the model system for understanding mycotoxin synthesis in fruits. The overall goal of this proposal is to identify critical host and pathogen factors that mechanistically modulate P. expansumgenes and pathways to control activation of PAT production and virulence in host. Several fungal factors have been correlated with disease development in apples, including the production of PAT, acidification of apple tissue by the fungus, sugar content and the global regulator of secondary metabolism and development, LaeA. An increase in sucrose molarity in the culture medium from 15 to 175 mM negatively regulated laeAexpression and PAT accumulation, but, conversely, increased creAexpression, leading to the hypothesis that CreA could be involved in P. expansumPAT biosynthesis and virulence, possibly through the negative regulation of LaeA. We found evidence for CreAtranscriptional regulation of laeA, but this was not correlated with PAT production either in vitro or in vivo, thus suggesting that CreA regulation of PAT is independent of LaeA. Our finding that sucrose, a key ingredient of apple fruit, regulates PAT synthesis, probably through suppression of laeAexpression, suggests a potential interaction between CreA and LaeA, which may offer control therapies for future study. We have also identified that in addition to PAT gene cluster, CreA regulates other secondary metabolite clusters, including citrinin, andrastin, roquefortine and communesins, during pathogenesis or during normal fungal growth. Following creation of P. expansumpacCknockout strain, we investigated the involvement of the global pH regulator PacC in fungal pathogenicity. We demonstrated that disruption of the pH signaling transcription factor PacC significantly decreased the virulence of P. expansumon deciduous fruits. This phenotype is associated with an impairment in fungal growth, decreased accumulation of gluconic acid and reduced synthesis of pectolytic enzymes. We showed that glucose oxidase- encoding gene, which is essential for gluconic acid production and acidification during fruit colonization, was significantly down regulated in the ΔPepacCmutant, suggesting that gox is PacC- responsive gene. We have provided evidence that deletion of goxgene in P. expansumled to a reduction in virulence toward apple fruits, further indicating that GOX is a virulence factor of P. expansum, and its expression is regulated by PacC. It is also clear from the present data that PacC in P. expansumis a key factor for the biosynthesis of secondary metabolites, such as PAT. On the basis of RNA-sequencing (RNA-seq) analysis and physiological experimentation, the P. expansumΔlaeA, ΔcreAand ΔpacCmutants were unable to successfully colonize apples for a multitude of potential mechanisms including, on the pathogen side, a decreased ability to produce proteolytic enzymes and to acidify the environment and impaired carbon/nitrogen metabolism and, on the host side, an increase in the oxidative defence pathways. Our study defines these global regulatory factors and their downstream signalling pathways as promising targets for the development of strategies to fight against this post-harvest pathogen.
8

Family Therapists Supporting the Hosts of Ukrainian Family (recording). ACAMH, December 2022. http://dx.doi.org/10.13056/acamh.21757.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Following the response teams of Systemic Therapists have delivered face to face and online workshops for people hosting Ukrainians with a view to helping them prepare for the task and to support them throughout the process. This webinar discusses what has been helpful, what’s been learnt, and future planning.
9

Internet‐delivered cognitive behavior therapy with minimal therapist support for anxious children and adolescents: predictors of response. ACAMH, June 2020. http://dx.doi.org/10.13056/acamh.12098.

Full text
APA, Harvard, Vancouver, ISO, and other styles

To the bibliography